Rexit Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 40.18%
(FY 2022)
- Profit 27.55%
(FY 2022)
- Ebitda 71.03%
(FY 2022)
- Net Worth 1007.73%
(FY 2022)
- Total Assets 0.37%
(FY 2022)
About Rexit Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rakesh Kumar and Nimka Rani serve as directors at the Company.
- CIN/LLPIN
U51909PB2017PTC046135
- Company No.
046135
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Feb 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Patiala, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Rexit Pharmaceutical Private Limited offer?
Rexit Pharmaceutical Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Ayurvedic Herbal Syrups & Tonics, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Common Disease Medicines, Antihistamines, Brain & Nervous System Drugs, Immunomodulator Drugs, Osteoporosis Medications, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Rexit Pharmaceutical?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rakesh Kumar | Director | 02-Feb-2024 | Current |
Nimka Rani  | Director | 14-Feb-2017 | Current |
Financial Performance of Rexit Pharmaceutical.
Rexit Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 40.18% increase. The company also saw a substantial improvement in profitability, with a 27.55% increase in profit. The company's net worth Soared by an impressive increase of 1007.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rexit Pharmaceutical?
In 2019, Rexit Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rexit Pharmaceutical?
Unlock and access historical data on people associated with Rexit Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rexit Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rexit Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
